Dezocine

This classification denotes an opioid receptor agonist and opioid with the molecular formula C16H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VHX8K5SV4X, chemically known as 5,11-methanobenzocyclodecen-3-ol, 13-amino-5,6,7,8,9,10,11,12-octahydro-5-methyl-, (5alpha,11alpha,13s*)-, (-)- but generally known as dezocine, which bears US NIH Compound Identifier 40841. European Medicines Agency schedules Dezocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07059MIG. The term DEZOCINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules dezocine in its Anatomical Therapeutic Chemical (ATC) Classification. DEZOCINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dezocine under HS 29222900 and SITC 51462. As of Q4 2014, DEZOCINE remains the US FDA Preferred Term for this commodity. Dezocine bears US NLM identifiers UMLS ID C0057626 and NCI Concept Code C65374. SMILES: OC1CC2C3(C(N)C(CC2CC1)CCCCC3)C.